United States · Wires & real time · PR Newswire

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

Published by PR Newswire · United States 1 h ago

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Associated Press (Business)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Dow Jones Newswires

Rethinking AI in Enterprise Intelligence

MT Newswires

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

Share

Also worth reading

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows